Brokerages Set $5.50 Price Target for Harvard Bioscience, Inc. (HBIO)
Shares of Harvard Bioscience, Inc. (NASDAQ:HBIO) have received a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that cover the company, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy recommendation.
Analysts have set a 12 month consensus price objective of $5.50 for the company and are anticipating that the company will post $0.05 EPS for the current quarter, according to Zacks. Zacks has also given Harvard Bioscience an industry rank of 76 out of 265 based on the ratings given to its competitors.
Hedge funds have recently bought and sold shares of the company. Northern Trust Corp lifted its position in shares of Harvard Bioscience by 5.2% during the 2nd quarter. Northern Trust Corp now owns 86,205 shares of the medical instruments supplier’s stock valued at $220,000 after buying an additional 4,260 shares in the last quarter. New York State Common Retirement Fund purchased a new position in shares of Harvard Bioscience during the 3rd quarter valued at about $321,000. Algert Global LLC lifted its position in shares of Harvard Bioscience by 31.0% during the 3rd quarter. Algert Global LLC now owns 149,094 shares of the medical instruments supplier’s stock valued at $559,000 after buying an additional 35,276 shares in the last quarter. Ameriprise Financial Inc. purchased a new position in shares of Harvard Bioscience during the 2nd quarter valued at about $752,000. Finally, Granahan Investment Management Inc. MA lifted its position in shares of Harvard Bioscience by 80.7% during the 3rd quarter. Granahan Investment Management Inc. MA now owns 537,467 shares of the medical instruments supplier’s stock valued at $2,016,000 after buying an additional 240,055 shares in the last quarter. 61.68% of the stock is currently owned by hedge funds and other institutional investors.
Harvard Bioscience (NASDAQ:HBIO) last posted its quarterly earnings data on Thursday, October 26th. The medical instruments supplier reported $0.03 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $0.03. Harvard Bioscience had a positive return on equity of 1.11% and a negative net margin of 3.16%. The firm had revenue of $25.05 million for the quarter, compared to analysts’ expectations of $24.60 million. sell-side analysts predict that Harvard Bioscience will post 0.05 earnings per share for the current year.
Harvard Bioscience Company Profile
Harvard Bioscience, Inc is a developer, manufacturer and marketer of a range of scientific instruments, systems and lab consumables used for basic research, drug discovery, clinical and environmental testing. The Company’s products are sold to thousands of researchers in over 100 countries through its global sales organization, Websites, catalogs and through distributors.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.